Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges

被引：24

作者：

Oh, So Won ^{[1
,2
]}

Cheon, Gi Jeong ^{[2
]}

机构：

[1] Seoul Natl Univ, Dept Nucl Med, Boramae Med Ctr, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea

[2] Seoul Natl Univ, Coll Med, Dept Nucl Med, Seoul 03080, South Korea

来源：

KOREAN JOURNAL OF RADIOLOGY | 2018年 / 19卷 / 05期

基金：

新加坡国家研究基金会;

关键词：

Prostate cancer; Prostate-specific membrane antigen; Prostate-specific PET tracers; PET/MRI; Recurrence; GA-68-LABELED PSMA LIGAND; LYMPH-NODE DISSECTION; RADICAL PROSTATECTOMY; RADIATION-DOSIMETRY; RADIOLIGAND THERAPY; GA-68-PSMA PET/CT; LOCAL RECURRENCE; BIOCHEMICAL RECURRENCE; BONE-SCINTIGRAPHY; EAU GUIDELINES;

D O I：

10.3348/kjr.2018.19.5.819

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The aim of this systematic review was to describe the characteristics of prostate-specific membrane antigen (PSMA)targeting PET and their clinical applications in prostate cancer patients. There have been major strides in the design, synthesis of PSMA-targeting PET tracers over the past several years. PSMA-targeting PET tracers can be categorized, according to positron emitters and targeting strategies for the PSMA. The majority of PSMA PET studies has been focused on patients with biochemical recurrence, but additional values of PSMA PET have also been investigated for use in primary staging, treatment planning, response evaluation, and PSMA radioligand therapy. PSMA PET is expected to bring improvements in the management of patients, but the impact of improved diagnosis by PSMA on overall survival remains unanswered. Many challenges still await PSMA PET to expedite the use in the clinical practice. At this early stage, prospective multicenter trials are needed to validate the effectiveness and usefulness of PSMA PET.

引用

页码：819 / 831

页数：13

共 81 条

[1] Baseline staging of newly diagnosed prostate cancer: A summary of the literature [J].

Abuzallouf, S ;

Dayes, I ;

Lukka, H .

JOURNAL OF UROLOGY, 2004, 171 (06) :2122-2127

[2]

Ackerstaff E, 2001, CANCER RES, V61, P3599

[3] Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience [J].

Afshar-Oromieh, A. ;

Haberkorn, U. ;

Schlemmer, H. P. ;

Fenchel, M. ;

Eder, M. ;

Eisenhut, M. ;

Hadaschik, B. A. ;

Kopp-Schneider, A. ;

Roethke, M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (05) :887-897

[4] PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions [J].

Afshar-Oromieh, A. ;

Malcher, A. ;

Eder, M. ;

Eisenhut, M. ;

Linhart, H. G. ;

Hadaschik, B. A. ;

Holland-Letz, T. ;

Giesel, F. L. ;

Kratochwil, C. ;

Haufe, S. ;

Haberkorn, U. ;

Zechmann, C. M. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :486-495

[5] Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing [J].

Afshar-Oromieh, Ali ;

Hetzheim, Henrik ;

Kuebler, Wolfgang ;

Kratochwil, Clemens ;

Giesel, Frederik L. ;

Hope, Thomas A. ;

Eder, Matthias ;

Eisenhut, Michael ;

Kopka, Klaus ;

Haberkorn, Uwe .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (09) :1611-1620

[6] The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J].

Afshar-Oromieh, Ali ;

Hetzheim, Henrik ;

Kratochwil, Clemens ;

Benesova, Martina ;

Eder, Matthias ;

Neels, Oliver C. ;

Eisenhut, Michael ;

Kuebler, Wolfgang ;

Holland-Letz, Tim ;

Giesel, Frederik L. ;

Mier, Walter ;

Kopka, Klaus ;

Haberkorn, Uwe .

JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) :1697-1705

[7] The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer [J].

Afshar-Oromieh, Ali ;

Avtzi, Eleni ;

Giesel, Frederik L. ;

Holland-Letz, Tim ;

Linhart, Heinz G. ;

Eder, Matthias ;

Eisenhut, Michael ;

Boxler, Silvan ;

Hadaschik, Boris A. ;

Kratochwil, Clemens ;

Weichert, Wilko ;

Kopka, Klaus ;

Debus, Juergen ;

Haberkorn, Uwe .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (02) :197-209

[8] Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer [J].

Afshar-Oromieh, Ali ;

Zechmann, Christian M. ;

Malcher, Anna ;

Eder, Matthias ;

Eisenhut, Michael ;

Linhart, Heinz G. ;

Holland-Letz, Tim ;

Hadaschik, Boris A. ;

Giesel, Frederik L. ;

Debus, Juergen ;

Haberkorn, Uwe .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (01) :11-20

[9] Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer [J].

Ahmadzadehfar, Hojjat ;

Eppard, Elisabeth ;

Kuerpig, Stefan ;

Fimmers, Rolf ;

Yordanova, Anna ;

Schlenkhoff, Carl Diedrich ;

Gaertner, Florian ;

Rogenhofer, Sebastian ;

Essler, Markus .

ONCOTARGET, 2016, 7 (11) :12477-12488

[10] 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy [J].

Baum, Richard P. ;

Kulkarni, Harshad R. ;

Schuchardt, Christiane ;

Singh, Aviral ;

Wirtz, Martina ;

Wiessalla, Stefan ;

Schottelius, Margret ;

Mueller, Dirk ;

Klette, Ingo ;

Wester, Hans-Juergen .

JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) :1006-1013

← 1 2 3 4 5 6 7 8 9 →